Allurion Technologies, Inc. (NYSE: ALUR), a pioneer in metabolically healthy weight loss, today announced the publication of the first peer-reviewed study on the consecutive use of the Allurion Smart Capsule, a first of its kind, swallowable, procedure-less weight-loss device.
Published in Obesity Surgery, a leading international journal dedicated to the treatment of obesity and metabolic disease, the multicenter, retrospective study demonstrates that two consecutive treatments can achieve average total body weight loss of 22.1% (19.3 kg), results comparable to bariatric surgery and high-dose GLP-1 therapy.
The study included 121 overweight adults (BMI of 25 to 30) and adults with obesity (BMI of 30 and above) across 11 international sites. No serious device-related adverse events were reported.
“This study provides robust evidence that consecutive use of the Allurion Smart Capsule is both safe and effective,” said Dr. Roberta Ienca, the Senior Author of the study and Medical Doctor at Nuova Villa Claudia Clinic in Rome, Italy.
”The study design mirrors the approach used in AUDACITY, the company’s FDA pivotal study, reinforcing the potential of consecutive Smart Capsule use as a first-line therapy for higher BMI patients who require more than 20% weight loss but are unwilling or ineligible to undergo surgery.
ALUR shares closed Monday at $2.05.
